Research Testimonials

Making an Informed Decision As a Family

4 mins WATCH NOW

Jewel is a teenager living with sickle cell disease. She and her mother, Paula make informed decision about participating in clinical studies.

My Contribution to Clinical Studies

3 mins WATCH NOW

Ada Gonzalez lives with sickle cell disease and enrolled in a clinical study decades ago that she benefits from today.

Research for Adults Aging with Sickle Cell

3 mins WATCH NOW

Andre, an adult living with sickle cell disease, talks about the need for treatment options for the aging and future generations with sickle cell disease.


Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease

21 Jul 2021

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that they have entered a non-exclusive research collaboration to evaluate the use of  JSP191, Jasper’s anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning agent with ARU-1801, Aruvant’s investigational […]

Sickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study

20 Jul 2021

Sickle cell disease (SCD) was associated with a significantly increased risk of COVID-19-related hospitalization and death in adults, U.K. researchers found.

Emmaus Life Sciences Announces Submission of Endari® Marketing Authorization Application in Kuwait

15 Jul 2021

Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today the submission of its application for Marketing Authorization (MA) for Endari® to the Kuwait Drug and Food Control (KDFC).

Join our newsletter

We send occasional updates that feature new trials, and other great tips. We will not spam you.

Have a question?